Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

HIV Drug Development: In Vitro Efficacy Evaluations

This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.

Main Areas of Focus

  • To fill specific gaps in an investigator’s drug development plan as they advance their product toward clinical investigation
  • To help investigators obtain data to get additional funding
  • To help with prospective partnerships
  • To help getting regulatory permission to continue

Support Services

Assays that can be provided include:

  • Evaluation against HIV-1, HIV-2, SIV, or SHIV
  • Evaluation in established T-cell lines, peripheral blood mononuclear cells (PBMCs), or macrophages
  • Evaluation against clinical isolates from different HIV subtypes
  • Evaluation against drug resistant virus isolates
  • Evaluation of products as single agents or in combination with other products
  • Evaluation as specific inhibitors of HIV-1 Tat and Rev function

Additional tasks that can be provided under this service include:

  • Generation of drug-resistant HIV isolates
  • Genotypic and phenotypic characterization of drug-resistant HIV isolates
  • Mode of action studies

Adaptation of an investigator’s target-based assay to a high-throughput platform, followed by screening of one or more commercially available chemical libraries in that assay.

Investigators seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf.

Who Can Use This Resource

  • Investigators must be conducting HIV research.
  • Compounds must previously have been successfully synthesized.
  • Investigators must have a defined product of known chemical structure.
  • Investigators must have preliminary data to support the continued development of the product.

Products must have already been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.

How To Get Started

Content last reviewed on November 17, 2017